Judge Tosses Preempted Claims From Aredia Suits

Law360, New York (July 28, 2008, 12:00 AM EDT) -- Playing the federal-law trump card, Novartis Pharmaceuticals Corp. has prevailed in its continuing bid to toss failure-to-warn claims from cases in the multidistrict litigation over its bone cancer drugs Aredia and Zometa.

The drugmaker won its motion for partial summary judgment dismissing the claims from eight Texas-based plaintiffs in a court order Friday, after arguing that approval by the U.S. Food and Drug Administration shielded it from liability.

In their complaints to the U.S. District Court for the Middle District of Tennessee, the eight plaintiffs had...
To view the full article, register now.